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Abstract: In the past 10 years, positron emission tomography
(PET), usually with 18F-fluoro-2-deoxy-D-glucose (FDG), has be-
come an important imaging modality in patients with lung cancer.
FDG-PET is recommended for the diagnosis of indeterminate pul-
monary nodules, for which it is significantly more accurate than
computed tomography (CT) in the distinction between benign and
malignant lesions. A large body of evidence convincingly demon-
strates that loco-regional lymph node staging by FDG-PET (in
correlation with CT images) is significantly superior to CT alone,
with a negative predictive value equal or even superior to medias-
tinoscopy. FDG-PET also improves extrathoracic staging through
detection of lesions missed at conventional imaging or characteriza-
tion of lesions that remain equivocal on conventional imaging.
Ongoing studies now concentrate on more advanced clinical appli-
cations, such as the planning of radiotherapy, the response evalua-
tion after the induction of therapy, the early detection of recurrence,
and the use in lung cancer screening. Technical innovations, such as
PET cameras with better spatial resolution, or new radiopharmaceu-
tical probes to study applications of PET in molecular biology hold
promise for future refinements in this field.
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The use of positron emission tomography (PET) with18F-fluoro-2-deoxy-D-glucose (FDG) in oncology is
based on its ability to visualize the differences among the
glucose metabolism of tissues. Neoplastic cells have a much
higher rate of glycolysis compared with non-neoplastic cells
and an increased cellular uptake of glucose, because of an
increased expression of glucose transport proteins. FDG un-
dergoes the same cellular uptake as glucose but is metaboli-
cally trapped and accumulated in the neoplastic cell after
phosphorylation by hexokinase. The preferential accumula-
tion of FDG in neoplastic cells permits differentiation be-
tween benign and malignant tissue. In this way, FDG-PET
complements the anatomic information on standard imaging
with “metabolic” information.
FDG-PET has become an important lung cancer imag-
ing tool. Current recommendations include the diagnosis of
lung cancer as well as loco-regional and distant staging of
non–small-cell lung cancer (NSCLC). Several innovative
techniques and clinical applications are being studied.
Diagnosis of Lung Cancer
PET has been studied extensively in the diagnosis of
indeterminate lung lesions. The technique has been proven to
be significantly more accurate than computed tomography
(CT) in differentiating benign from malignant lesions as
small as 1 cm. An overall sensitivity of 96% (range, 83–
100%), specificity of 79% (range, 52–100%), and accuracy of
91% (range, 86–100%) can be expected.1,2 False-negative
results can occur in subcentimetric lesions because a critical
mass of metabolically active malignant cells is required for
PET diagnosis. Even when they are larger than 1 cm, bron-
choalveolar cell carcinomas, which often have a distinct
pattern on CT (ground-glass opacity), may exhibit little or no
FDG uptake. False-positive FDG uptake is seen in inflam-
matory conditions and granulomatous diseases. Because of its
high negative predictive value, PET excludes malignancy
correctly in the vast majority of cases. Thoracotomy can be
avoided in such patients, and follow-up with radiographic or
CT scan at 3, 6, 12, and 24 months can be advised.3 As the
specificity is only 79%, the positive predictive value will be
lower. In clinically suspicious cases, further investigations for
detection of infectious or granulomatous disorders are indi-
cated. If there is doubt, solitary nodules with high FDG
uptake require resection.
Loco-regional and Extrathoracic Staging
A large number of accuracy studies previously summa-
rized in six meta-analyses,2,4–8 have convincingly demon-
strated that PET is a superior imaging technique for medias-
tinal lymph node staging in potentially operable NSCLC. For
the distinction between N0-1 and N2-3 patients, the review
yielded an overall sensitivity of 89% (range, 67–100%) with
a specificity of 92% (range, 79–100%) and an accuracy of
90% (range, 78–100%). For CT, the sensitivity was 65%
(range, 20–86%), specificity was 80% (range, 43–90%), and
accuracy was 75% (range, 52–79%).1 Interpretation of PET
images is improved by visual correlation with CT through
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better localization of PET abnormalities with the help of the
anatomical detail of CT. Of major clinical importance is the
good negative predictive value of PET in lymph node staging.
Patients with mediastinal PET-negative results may be ade-
quately staged without invasive procedures and can proceed
directly to thoracotomy,9,10 provided that some conditions are
respected: (1) sufficient FDG uptake in the primary tumor; (2)
absence of a central tumor or important hilar lymph node
disease that may obscure coexisting N2 disease on PET
(Figure 1); and (3) use of a dedicated PET camera.11 Al-
though the positive predictive value is reasonable, false-
positive results can be obtained in the case of anthracosilico-
sis, infection, or granulomatous disorders. In these patients,
confirmation of N2 or N3 disease by mediastinoscopy is
mandatory to ensure that no patient with resectable N0 or N1
disease is denied the chance of curative surgery.
As for extrathoracic staging, PET is a useful adjunct to
conventional imaging. PET offers an additional value in the
detection of distant metastases in potentially operable
NSCLC by two means.12 First, there is the detection of
unexpected metastatic spread. After a negative conventional
staging, unknown metastases were found on PET in 5 to 29%
of patients. The incidence of occult metastatic lesions in-
creases with increasing pre-PET stage from 8% in stage I, to
18% in stage II, to 24% in stage III.13 Second, PET is able to
determine the nature of equivocal lesions on conventional
imaging, present in 7 to 19% of patients. Exclusion of
malignancy by PET requires caution in the case of a small
lesion (1 cm).
As a whole, PET has a positive impact on overall
staging and patient management.14 The use of PET imaging
for clinical staging results in a stage different from that
determined by conventional methods in 27 to 62% of patients
with NSCLC. Up-staging is more frequent than down-staging
and is related mainly to the detection of unexpected distant
lesions by PET. Across series, this leads to a change in patient
management for 25 to 52% of patients (mainly changes in
treatment intent from curative to palliative).12 In one study,
an intramodality change was reported in 26% of the pa-
tients.15 There is also randomized evidence that PET reduces
the need for invasive procedures and futile surgery.16
Whether it seemingly improves survival because of stage
migration or whether it truly improves survival because of
better therapeutic strategies remains to be determined.
Innovation
Different innovative clinical applications of PET in the
field of lung cancer are studied intensively.
In a recent systematic review on the use of PET for
prognostic and therapeutic assessment,17 we summarized that
there is good evidence that FDG uptake on PET has inde-
pendent prognostic value in patients with newly diagnosed
NSCLC.
PET is more sensitive than CT in measuring the bio-
logical effects of anticancer therapy, and it can be used for
additional early response assessment in clinical trials. Differ-
ent studies have also used PET to evaluate response in
clinical practice (Figure 2), but better standardization of the
technique and response criteria is needed before taking this to
large-scale use.
An increasing number of studies have examined the
role of PET in restaging after induction therapy in multimo-
dality approaches for locally advanced lung cancer. The
assessment of mediastinal lymph nodes is better than that
with CT but not as good as in untreated patients, especially
after chemoradiotherapy induction. Lack of clearance of
mediastinal lymph nodes or unchanged FDG uptake in the
primary tumor usually denotes a poor outcome after multi-
modality treatment.
Good prospective evidence documents the superiority
of PET over CT in the correct identification of recurrent lung
cancer.
The additional value of PET has also been explored in
lung cancer screening studies. One of the problems associated
with screening is the potential need for invasive procedures in
patients with benign nodules. One screening study examined
the selective use of PET in screen-detected nodules larger
than or equal to 7 mm.18 PET was correctly positive in eight
of nine prevalence cancers (an 8-mm adenocarcinoma was
missed), and in 10 of 11 incidence cancers (with one pre-
dominantly bronchoalveolar tumor of 11 mm missed).
More fields of innovation, discussed in other contribu-
tions to this series, are the use of PET/CT fusion cameras, the
use of PET/CT for radiotherapy planning, and the integration
of new imaging techniques such as PET with biomarkers,
another rapidly evolving field in lung cancer research.
Finally, a large number of new tracers attempt to
examine the biological behavior of lung cancer in more detail
FIGURE 1. Patient with centrally located squamous cell car-
cinoma originating from the right upper lobe (A and B). Al-
though PET shows only one area of increased FDG uptake
without the suggestion of mediastinal lymph node metasta-
ses (C and D), a mediastinoscopy is indicated to rule out
adjacent lymph nodes.
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than FDG, with promising findings. For example, for lung
cancer proliferation, 11C-thymidine was the first radiotracer
for non-invasive in vivo imaging. The short half-life of 11C
and the rapid metabolism of 11C-thymidine in vivo made the
radiotracer less suitable for use. Recently, clinical experience
was gained with the thymidine analogue 3=-deoxy-3=-18fluo-
rothymidine (FLT), a more stable proliferation marker. FLT
is phosphorylated by thymidine kinase 1, which is present in
large quantity in proliferating lung cancer cells. The good
relationship between FLT uptake and tumor proliferation can
be exploited to improve the specificity of PET imaging in
solitary pulmonary nodules19 and may be useful to improve
the results with FDG when restaging patients who have
undergone induction chemo(radio)therapy for NSCLC.
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FIGURE 2. Patient with stage IIIA-N2 adenocarcinoma (peripheral lesion in the right upper lobe and right paratracheal
lymph node involvement). Good tumor response after cisplatin-based induction chemotherapy, both on CT (A and B) and on
FDG-PET (C and D). In the resection specimen, lymph node down-staging and only a few viable cells in the primary tumor
were found.
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